AZ's Tagrisso brings 'unprecedented' benefit in untreated NSCLC

09:47 EDT 16 Apr 2018 | pharmaphorum

AstraZeneca says its lung cancer drug Tagrisso has produced “unprecedented” survival benefit from first-line use in some patients with advanced disease. The UK pharma company tested the drug in first line in patients with locally advanced or metas...

Original Article: AZ's Tagrisso brings 'unprecedented' benefit in untreated NSCLC


More From BioPortfolio on "AZ's Tagrisso brings 'unprecedented' benefit in untreated NSCLC"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...